{"nctId":"NCT02110264","briefTitle":"Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)","startDateStruct":{"date":"2015-06"},"conditions":["Opioid Use Disorders"],"count":151,"armGroups":[{"label":"Vivitrol (XR-NTX)","type":"EXPERIMENTAL","interventionNames":["Drug: XR-NTX"]},{"label":"XR-NTX+PN","type":"EXPERIMENTAL","interventionNames":["Drug: XR-NTX","Behavioral: XR-NTX+PN"]},{"label":"ETAU","type":"ACTIVE_COMPARATOR","interventionNames":["Behavioral: ETAU"]}],"interventions":[{"name":"XR-NTX","otherNames":["long-acting naltrexone","Vivitrol"]},{"name":"XR-NTX+PN","otherNames":["Patient Navigator"]},{"name":"ETAU","otherNames":["Treatment-as-usual","Drug Education"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Be at least 18 years of age or older,\n2. Meet criteria for DSM-5 opioid use disorders,\n3. Be detained for at least 48 hours,\n4. Have an expected release date within one year,\n5. Plan to reside in area after release.\n\nExclusion Criteria:\n\n1. Have a medical (e.g., liver failure, congestive heart failure) or psychiatric condition (e.g., suicidal ideation, psychosis) that would make participation unsafe in the judgment of the medical staff or the PI,\n2. Have current or chronic pain or have plans to undergo pain treatment/therapy,\n3. Have known sensitivity to naltrexone or naloxone,\n4. Have participated in an investigational drug study within the past 30 days prior to screening,\n5. Be a nursing or pregnant female, or not agree to use a medically acceptable form of birth control such as oral contraceptives, barrier (diaphragm or condom), levonorgestrel implant, intra-uterine progesterone contraceptives system, medroxyprogesterone acetate contraceptive injection, or complete abstinence. Females who become pregnant during the course of the study will be withdrawn from the study and, if requested, will be provided with referrals for drug treatment and/or medical care,\n6. Have any pending legal action that could prohibit continued participation for the 24-week intervention period of the study, such as legal proceedings that could possibly result in incarceration,\n7. Have a current pattern of alcohol, benzodiazepine, or other depressant or sedative hypnotic use, as determined by the study physician which would preclude safe participation in the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Opioid Use","description":"The primary objective is to compare outcomes of the three intervention groups, based on self-reports at 6-months post-intervention.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Opioid Use Disorder","description":"Number of participants meeting DSM-5 OUD (opioid use disorder) criteria via modified CIDI-2 Substance Abuse Module","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":53},"commonTop":["Pain at injection site","Precipitated withdrawal","photophobia","Blurred vision"]}}}